Post-earnings recap
Reported
Mon, May 7, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that Krystal Biotech is still in a development phase, as evidenced by the negative EPS. Despite this, the stock rose by 2.68%, likely due to positive sentiment around their ongoing projects and management's optimistic tone. Investors may be encouraged by the potential for future growth.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.21 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management conveyed a sense of cautious optimism regarding the company's future. They emphasized their commitment to advancing their product pipeline.
Management highlighted ongoing developments in their pipeline.
They expressed confidence in future projects despite current losses.